 The FDA said Monday it will perform a speedy review of Sarepta Therapeutics muscular dystrophy gene therapy, and SRPT stock jumped. The post Sarepta Surges As It Nears The Finish Line With A Muscular Dystrophy Gene Therapy appeared first on Investors Business Daily. 